

1647

#16

RAW SEQUENCE LISTING  
 PATENT APPLICATION: US/09/322,289

DATE: 01/05/2001  
 TIME: 14:28:00

ENTERED

Input Seq: A:\-47-4.app  
 Output Seq: N:\CRF3\01052001\I322289.raw

RECEIVED  
 JAN 16 2001  
 TECH CENTER 1800/2800

3 <110> APPLICANT: Schenk, Dale R.  
 4 <120> INVENTOR: Schenk, Dale R.  
 5 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
 8 <130> FILE FILING NO.: 152701-00174323  
 10 <140> CURRENT APPLICATION NUMBER: 09/322,289  
 11 <141> CURRENT FILING DATE: 1999-05-28  
 13 <160> NUMBER OF SEQ ID NOS: 5  
 15 <170> SOFTWARE: Patent In Ver. 2.1  
 17 <210> SEQ ID NO: 1  
 18 <211> LENGTH: 42  
 19 <212> TYPE: PRT  
 20 <213> ORGANISM: Homo sapiens  
 22 <220> FEATURE:  
 23 <223> OTHER INFORMATION: human Abeta42 beta-amyloid peptide  
 25 <400> SEQUENCE: 1  
 26 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Glu Lys  
 27 1 5 10 15  
 28 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
 29 20 25 30  
 32 Gly Leu Met Val Gly Gly Val Val Ile Ala  
 33 35 40  
 36 <210> SEQ ID NO: 2  
 37 <211> LENGTH: 13  
 38 <212> TYPE: PRT  
 39 <213> ORGANISM: Artificial Sequence  
 41 <220> FEATURE:  
 42 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta1-12  
 43 peptide with carboxyl terminal Cys residue  
 44 inserted  
 45 <400> SEQUENCE: 2  
 47 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys  
 48 1 5 10  
 51 <210> SEQ ID NO: 3  
 52 <211> LENGTH: 6  
 53 <212> TYPE: PRT  
 54 <213> ORGANISM: Artificial Sequence  
 56 <220> FEATURE:  
 57 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta1-5  
 58 peptide with carboxyl terminal Cys residue  
 59 inserted  
 61 <400> SEQUENCE: 3  
 62 Asp Ala Glu Phe Arg Cys  
 63 1 5  
 66 <210> SEQ ID NO: 4  
 67 <211> LENGTH: 12  
 68 <212> TYPE: PRT  
 69 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING  
 PATENT APPLICATION: US/09/322,289  
 DATE: 11/05/2001  
 TIME: 14:28:06

Input File: A:\-47-4.app  
 Output File: N:\CRF3\01052001\I322289.raw

71 <220> FEATURE:  
 72 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta13-42  
 73 peptide with carboxyl terminal Cys residue  
 74 inserted  
 75 <220> FEATURE:  
 76 <221> NAME/KEY: MOD\_RES  
 77 <222> LOCATION: (2)  
 78 <223> OTHER INFORMATION: Xaa amino heptanoic acid  
 81 <100> SEQUENCE: 1  
 82 Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala  
 83 1 5 10  
 86 <210> SEQ ID NO: 5  
 87 <211> LENGTH: 19  
 88 <212> TYPE: PRP  
 89 <213> ORIGIN: Artificial Sequence  
 91 <220> FEATURE:  
 92 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta13-28  
 93 peptide with carboxyl terminal Cys residue  
 94 inserted and two added Gly residues  
 96 <220> FEATURE:  
 97 <221> NAME/KEY: MOD\_RES  
 98 <222> LOCATION: (1)  
 99 <223> OTHER INFORMATION: Xaa acetyl histidine  
 101 <100> SEQUENCE: 5  
 102 Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys  
 103 1 5 10 15  
 105 Gly Gly Cys

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/322,289

DATE: 01/05/2001

TIME: 11:28:07

Input Set: A:\-47-4.app

Output Set: N:\CRF3\01052001\I322289.raw

INFO: H:341 W: (46) "n" or "Xaa" used. For Seq 10004  
INFO: H:341 W: (46) "n" or "Xaa" used. For Seq 10005

RECEIVED  
JAN 16 2001  
TECH CENTER 1600/2000